Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BWAYNYSE:CATXNASDAQ:LNSRNASDAQ:TMDIF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBWAYBrainsway$13.22+0.9%$10.23$5.67▼$13.25$249.79M1.3267,611 shs33,273 shsCATXPerspective Therapeutics$3.76+3.9%$2.82$1.60▼$16.55$279.10M1.091.08 million shs4.16 million shsLNSRLENSAR$12.76+1.7%$13.43$3.50▼$17.31$150.47M0.5290,721 shs1.33 million shsTMDIFTitan Medical$0.29$0.28$0.03▼$1.00$32.62M1.2674,785 shs68 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBWAYBrainsway0.00%+21.17%+26.75%+42.15%+112.20%CATXPerspective Therapeutics0.00%+8.67%+39.26%+70.91%-60.46%LNSRLENSAR0.00%+2.82%-7.00%-9.70%+190.66%TMDIFTitan Medical+0.32%+32.47%-3.02%-25.71%+687.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBWAYBrainsway1.4251 of 5 stars1.53.00.00.02.10.81.9CATXPerspective Therapeutics3.164 of 5 stars4.61.00.00.03.02.50.0LNSRLENSAR1.2903 of 5 stars2.03.00.00.02.22.50.0TMDIFTitan MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBWAYBrainsway 3.00Buy$14.257.79% UpsideCATXPerspective Therapeutics 3.18Buy$12.56233.92% UpsideLNSRLENSAR 2.00Hold$15.0017.55% UpsideTMDIFTitan Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TMDIF, LNSR, CATX, and BWAY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/9/2025BWAYBrainswayHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.004/7/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $10.003/31/2025CATXPerspective TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBWAYBrainsway$41.02M6.09$0.25 per share53.02$3.31 per share3.99CATXPerspective Therapeutics$1.43M195.17N/AN/A$2.67 per share1.41LNSRLENSAR$53.49M2.81N/AN/A$0.42 per share30.38TMDIFTitan Medical$17.63M1.85$14.30 per share0.02$1.05 per share0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBWAYBrainsway$2.92M$0.2066.1082.63N/A9.01%7.35%4.72%8/5/2025 (Estimated)CATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)LNSRLENSAR-$31.40M-$4.85N/A∞N/A-99.17%-737.30%-81.69%8/6/2025 (Estimated)TMDIFTitan Medical$6.95M$0.05N/A∞N/AN/A-82.31%-51.47%N/ALatest TMDIF, LNSR, CATX, and BWAY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BWAYBrainsway$0.02$0.04+$0.02$0.04$11.45 million$11.54 million5/8/2025Q1 2025LNSRLENSAR-$0.1550-$2.32-$2.1650-$2.32$13.40 million$11.53 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBWAYBrainswayN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/ATMDIFTitan MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBWAYBrainswayN/A5.034.75CATXPerspective TherapeuticsN/A9.609.60LNSRLENSARN/A1.811.25TMDIFTitan MedicalN/A3.733.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBWAYBrainsway30.11%CATXPerspective Therapeutics54.66%LNSRLENSAR40.15%TMDIFTitan Medical0.03%Insider OwnershipCompanyInsider OwnershipBWAYBrainsway19.00%CATXPerspective Therapeutics3.72%LNSRLENSAR38.52%TMDIFTitan Medical0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBWAYBrainsway12018.90 million15.31 millionNot OptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableLNSRLENSAR11011.79 million7.25 millionOptionableTMDIFTitan Medical50114.04 million4.56 millionNot OptionableTMDIF, LNSR, CATX, and BWAY HeadlinesRecent News About These CompaniesTitan Medical Group Launches Titan Workforce Solutions: Launches to Transform Healthcare StaffingApril 29, 2025 | businesswire.comTitan Nurse Staffing, LLC and Titan Medical Group, LLC Announce Merger to Streamline Healthcare Staffing ServicesApril 29, 2025 | businesswire.comTitan MRI acquires High Field MRI, expanding Titan MRI's service to North Central FloridaDecember 3, 2024 | msn.comAttack on Titan movie release date, trailer, changes, and everything else we know about The Last AttackNovember 6, 2024 | gamesradar.comGConavi Medical Corp. (formerly “Titan Medical Inc.”) Completes Business CombinationOctober 11, 2024 | globenewswire.comTitan Announces the Closing of Conavi's Private Placement of Subscription Receipts and Provides Update on the TransactionOctober 8, 2024 | globenewswire.comTitan Announces Resignations of DirectorsOctober 2, 2024 | globenewswire.comTitan Reports Voting Results from 2023 Annual General and Special MeetingSeptember 30, 2024 | globenewswire.comTitan Medical begins process to move to the TSX Venture ExchangeSeptember 30, 2024 | globenewswire.comConavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and ConaviSeptember 26, 2024 | globenewswire.comProxy Deadline Thursday September 26, 2024September 25, 2024 | globenewswire.comProxy Advisor Glass, Lewis & Co., Recommends Titan Shareholders Vote FOR the Amalgamation Between Titan and ConaviSeptember 19, 2024 | globenewswire.comA key employee says the Titan sub tragedy could have been preventedSeptember 18, 2024 | postregister.comPTitan Announces Conavi Medical to Present Overview at Titan Q&A SessionSeptember 16, 2024 | globenewswire.comIndependent Proxy Advisor, Institutional Shareholder Services (“ISS”), Recommends Titan Shareholders Vote FOR the Amalgamation Between Titan and ConaviSeptember 16, 2024 | globenewswire.comTitan Announces Q&A Session with ShareholdersSeptember 9, 2024 | globenewswire.comTitan Announces Filing of the Management Information Circular.September 6, 2024 | globenewswire.comTitan Medical | Morning BlendSeptember 3, 2024 | msn.comTitan Medical Inc. (QTNA.SG)August 24, 2024 | finance.yahoo.comTitan Medical Reports Operating and Financial Results for the Second Quarter 2024August 15, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTMDIF, LNSR, CATX, and BWAY Company DescriptionsBrainsway NASDAQ:BWAY$13.22 +0.12 (+0.92%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$13.05 -0.17 (-1.29%) As of 06/27/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Perspective Therapeutics NYSE:CATX$3.76 +0.14 (+3.87%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.81 +0.05 (+1.36%) As of 06/27/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.LENSAR NASDAQ:LNSR$12.76 +0.21 (+1.67%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$12.76 0.00 (0.00%) As of 06/27/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Titan Medical NASDAQ:TMDIF$0.29 0.00 (0.00%) As of 06/27/2025Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
